<DOC>
	<DOCNO>NCT01247116</DOCNO>
	<brief_summary>The purpose study evaluate strategy initiate double oral combination therapy bosentan sildenafil time diagnosis pulmonary arterial hypertension ( PAH ) preliminary way .</brief_summary>
	<brief_title>First-line Bosentan Sildenafil Combination Therapy Pulmonary Arterial Hypertension</brief_title>
	<detailed_description>Current treatment paradigm PAH suggest adopt goal therapy relatively objective parameter 6 minute walk distance determine add second oral agent ( 1 ) . This often entail observe deterioration patient single agent institute second one . This strategy could problematic , patient may never recover function lose due progressive PAH ( 2 ) . In addition , give malignant nature clinical course PAH many case nature underlie proliferative vasculopathy , argue alter paradigm resemble use cancer chemotherapy may appropriate ( 3 ) . That , `` induction '' therapy diagnosis multiple agent follow maintenance phase treatment might offer significant benefit patient . This open-label pilot study first investigate potential efficacy safety first-line combination strategy consecutive patient PAH contrast `` add-on '' strategy combination therapy . It serve basis consider large , multicenter investigation strategy . 1 . Hoeper M , et al . Eur Respir J . 2005 Nov ; 26 ( 5 ) :858-63 . 2 . Halpern SD , et al . Proc Am Thorac Soc . 2008 Jul 15 ; 5 ( 5 ) :631-5 . 3 . Provencher S , et al . Chest . 2005 Dec ; 128 ( 6 Suppl ) :622S-628S .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Patients symptomatic Functional Class III PAH follow category : Idiopathic ( IPAH ) , Familial ( FPAH ) , Associated connective tissue disease , Associated drug toxins PAH diagnose right heart catheterization , define : mean pulmonary arterial pressure ( mPAP ) ≥ 25 mmHg , PVR &gt; 3 mmHg/l/min ( Wood unit ) &gt; 240 dyn sec cm5 , pulmonary capillary wedge pressure ( PCWP ) ≤ 15 mmHg Baseline 6 MWT distance &gt; 150 &lt; 450 Treatment ERAs bosentan ; Treatment PDE5 inhibitor sildenafil ; Treatment prostanoid ; PAH associate thyroid disorder , glycogen storage disease , Gaucher disease , hereditary hemorrhagic telangiectasia , hemoglobinopathy , myeloproliferative disorder splenectomy ; valvular disease valvular lesion exclude echocardiogram within 2 year prior randomization Restrictive lung disease : total lung capacity ( TLC ) &lt; 60 % normal predict value ; Obstructive lung disease : forced expiratory volume/forced vital capacity ( FEV1/FVC ) &lt; 50 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>